维奈克拉联合阿扎胞苷治疗初治急性髓系白血病的可测量残留病反应与预后
在VIALE-A试验中,164例接受维奈克拉联合阿扎胞苷治疗并达复合完全缓解(CRc)的初治急性髓系白血病患者可评估可测量残留病(MRD)。41%达MRD<10⁻³者中位缓解持续时间、无事件生存期和总生存期均未达到,12个月估计值分别为81.2%、83.2%和94.0%;MRD≥10⁻³者中位值分别为9.7、10.6和18.7个月。多因素分析显示CRc且MRD<10⁻³是总生存期的强预测因素(校正风险比=0.285;95%CI 0.159-0.510;P<.001)。
要点
- VIALE-A试验中86%达CRc者可评估MRD,41%达MRD<10⁻³,59%为MRD≥10⁻³。
- MRD<10⁻³组12个月DoR、EFS、OS估计值分别为81.2%、83.2%、94.0%。
- MRD≥10⁻³组中位DoR、EFS、OS分别为9.7、10.6和18.7个月。
核心结论
- 接受维奈克拉联合阿扎胞苷治疗并达CRc且MRD<10⁻³的患者,其DoR、EFS和OS均长于MRD≥10⁻³的缓解患者。
研究设计与样本
- VIALE-A试验中接受维奈克拉联合阿扎胞苷治疗的患者,在基线、第1周期末及此后每3个周期采集骨髓穿刺样本进行中心多参数流式细胞术评估MRD。
- 本报告纳入190例达CRc患者中的164例(86%)可评估MRD者,MRD阴性定义为每1000个白细胞中残留原始细胞<1个(<10⁻³或0.1%),估计分析灵敏度为0.0037%-0.0027%。
主要发现
- 164例可评估MRD的CRc患者中,67例(41%)达MRD<10⁻³,97例(59%)为MRD≥10⁻³。
- MRD<10⁻³组中位DoR、EFS和OS均未达到,12个月估计值分别为81.2%、83.2%和94.0%。
- MRD≥10⁻³组中位DoR、EFS和OS分别为9.7、10.6和18.7个月。
- 多因素分析显示CRc且MRD<10⁻³是OS的强预测因素(校正风险比=0.285;95%CI 0.159-0.510;P<.001)。
关键数值与推荐
- MRD阴性定义为<10⁻³或0.1%,即每1000个白细胞中残留原始细胞<1个,估计分析灵敏度为0.0037%-0.0027%。
- CRc且MRD<10⁻³对OS的校正风险比为0.285(95%CI 0.159-0.510;P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10-3 in the VIALE-A trial. METHODS: The patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10-3 or 0.1%) with an estimated analytic sensitivity of 0.0037%-0.0027%. CRc, duration of remission (DoR), event-free survival (EFS), and overall survival (OS) were assessed. A multivariate Cox regression analysis identified prognostic factors associated with OS. RESULTS: One hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10-3 was achieved by 67 of 164 (41%), and 97 of 164 (59%) had MRD ≥ 10-3. The median DoR, EFS, and OS were not reached in patients with CRc and MRD < 10-3, and the 12-month estimates for DoR, EFS, and OS in this group were 81.2%, 83.2%, and 94.0%. Among patients with CRc and MRD ≥ 10-3, the median DoR, EFS, and OS were 9.7, 10.6, and 18.7 months. Multivariate analysis showed that CRc with MRD < 10-3 was a strong predictor of OS (adjusted hazard ratio = 0.285; 95% CI, 0.159 to 0.510; P < .001). CONCLUSION: Patients who achieved CRc and MRD < 10-3 with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10-3.
引用
- Pratz KW, Jonas BA, Pullarkat V, et al. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2021. PMID: 34910556. doi:10.1200/JCO.21.01546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。